MedTrace Logo

Developing Advanced Blood-Brain Barrier Permeability Imaging for Early AD

NCT03389698 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 27

Last updated 2024-01-30

No results posted yet for this study

Summary

Aging is the primary risk factor in aging-related dementia. An important initiating factor for the development and progression of cognitive impairment is disruption of the blood-brain barrier (BBB). BBB plays an important role in maintaining normal brain homeostasis and protecting neural tissues from toxins. It is hypothesized that such changes known to be common in aging and can be an early process that precedes Alzheimer's Disease (AD). The microvascular changes related to subtle BBB disruption can be measured with permeability-surface area (PS) derived from GRASP DCE-MRI acquired less than 10 minutes, and the patterns of increased PS in normal and abnormal aging are different.

Conditions

  • Alzheimer Disease

Interventions

DEVICE

GRASP Dynamic Contrast-Enhanced (DCE) MRI

Golden-angle Radial Sparse Parallel (GRASP) DCE MRI is an MRI sequence designed to improve spatial and temporal resolution while enabling retrospective reconstruction with flexible temporal resolution.

DEVICE

3T Brain Scan

Up to 60 minutes, a portion of which uses the GRASP DCE-MRI sequence.

DRUG

Gadolinium-based Contrast Agent (GBCA) for MRI

Gadavist/Gadobutrol is a gadolinium-based contrast agent indicated for intravenous use in diagnostic magnetic resonance imaging (MRI) in adults and children (2 years of age and older) to detect and visualize areas with disrupted blood brain barrier (BBB) and/or abnormal vascularity of the central nervous system.

Sponsors & Collaborators

Principal Investigators

  • Yulin Ge, MD · NYU Langone Health

Eligibility

Min Age
20 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2018-12-18
Primary Completion
2022-01-28
Completion
2023-07-11
FDA Device
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03389698 on ClinicalTrials.gov